NEW YORK, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Rain Oncology Inc. ("Rain" or the "Company") (NASDAQ:RAIN). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.
The investigation concerns whether Rain and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On or around April 22, 2021, Rain conducted its initial public offering ("IPO"), selling more than 7.35 million ...